Compound Guide
What Is Tirzepatide? Research Overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first of a class called “twincretins” — studied extensively in metabolic research. This guide covers its mechanism, structure, and research context. For laboratory research reference only.
Research Use Only: Tirzepatide supplied by TrueCanPeptides is for qualified in vitro laboratory research. Not for human or animal administration.
What Is Tirzepatide?
Tirzepatide is a 39-amino-acid synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual mechanism earned it the term “twincretin” in the research literature — a single molecule targeting two incretin hormone receptors simultaneously.
Developed and studied by Eli Lilly, tirzepatide represents the second generation of GLP-1-class research compounds after semaglutide. Its structure is based on a modified GIP sequence with GLP-1R agonism elements incorporated, a design approach distinct from earlier incretin analogues that built from the GLP-1 scaffold.
Dual Receptor Mechanism
The rationale for dual GIP/GLP-1 targeting is rooted in complementary receptor distribution. GLP-1R is predominantly expressed in pancreatic beta cells, hypothalamus, and gut. GIPR is expressed in adipose tissue, bone, and also pancreatic beta cells. By targeting both, tirzepatide engages additional regulatory pathways not accessible to GLP-1 monoagonists.
| Receptor | Primary Expression | Research Impact |
|---|---|---|
| GLP-1R | Beta cells, hypothalamus, gut | Insulin secretion, satiety signalling, gastric emptying |
| GIPR | Adipose, beta cells, bone | Lipid metabolism, fat tissue regulation, bone turnover research |
Tirzepatide vs Semaglutide: Key Differences
The most fundamental distinction between tirzepatide and semaglutide in research is receptor breadth. Semaglutide is a pure GLP-1R agonist — its entire mechanism operates through that single receptor. Tirzepatide adds GIPR co-activation, which in clinical research programmes produced greater body weight reduction than equivalent doses of semaglutide — a finding that has attracted significant attention in metabolic disease research.
Structurally, semaglutide is built on a GLP-1 scaffold, while tirzepatide uses a GIP-based backbone with GLP-1R agonism introduced through modification of specific residues. This scaffold difference contributes to distinct receptor binding kinetics and selectivity profiles.
📊 Full three-way comparison: Semaglutide vs Tirzepatide vs Retatrutide →
Research Literature Context
The SURPASS clinical trial programme evaluated tirzepatide extensively in human subjects, generating peer-reviewed publications across metabolic endpoints. The SURMOUNT programme followed, focusing on body composition outcomes. Together, these programmes produced one of the largest datasets on any incretin-based peptide. Preclinical research complementing these trials investigated mechanisms in rodent and in vitro models.
Ongoing research areas involving tirzepatide include: hepatic steatosis and NASH models, cardiac metabolism research, adipocyte biology, and comparison studies with retatrutide (triple agonist) examining whether glucagon receptor addition provides incremental benefit over dual agonism.
Chemistry and Storage
Tirzepatide has a molecular weight of approximately 4,813 Da and a 39-amino-acid sequence. It is supplied as a lyophilized powder and should be stored at −20°C in a sealed container away from light and moisture. Reconstitute with bacteriostatic water per standard peptide laboratory protocol. See Reconstitution Guide.
FAQs
What makes tirzepatide a “twincretin”?
The term “twincretin” reflects tirzepatide’s dual agonism at two incretin hormone receptors — GLP-1R and GIPR. Incretins are gut hormones that stimulate insulin secretion. A molecule that activates both incretin receptors simultaneously is a “twin” incretin agonist.
How does tirzepatide compare to retatrutide?
Retatrutide is a triple agonist — it adds glucagon receptor (GCGR) activity to the dual GIP/GLP-1 targeting of tirzepatide. This third receptor, GCGR, is involved in hepatic glucose production and energy expenditure regulation. Retatrutide is currently in Phase II/III investigation; its triple-agonism profile is under active study. See our full comparison.
Is tirzepatide available as a research peptide in Canada?
TrueCanPeptides supplies tirzepatide as a research compound for qualified laboratory use within Canada. It is not supplied as a pharmaceutical product and is not intended for human administration. See our Research Peptides Canada overview.
Tirzepatide is supplied by TrueCanPeptides for qualified in vitro laboratory research only. Not for human or animal administration. Not evaluated or approved by Health Canada.
Related: Tirzepatide 20mg | Sema vs Tirze vs Reta | What Is Semaglutide? | What Is Retatrutide?